title: Introduction to thematic minireview series: Development of human therapeutics based on induced pluripotent stem cell (iPSC) technology.
abstract: With the advent of human induced pluripotent stem cell (hiPSC) technology, it is now possible to derive patient-specific cell lines that are of great potential in both basic research and the development of new therapeutics for human diseases. Not only do hiPSCs offer unprecedented opportunities to study cellular differentiation and model human diseases, but the differentiated cell types obtained from iPSCs may become therapeutics themselves. These cells can also be used in the screening of therapeutics and in toxicology assays for potential liabilities of therapeutic agents. The remarkable achievement of transcription factor reprogramming to generate iPSCs was recognized by the award of the Nobel Prize in Medicine to Shinya Yamanaka in 2012, just 6 years after the first publication of reprogramming methods to generate hiPSCs (Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007) Cell 131, 861-872). This minireview series highlights both the promises and challenges of using iPSC technology for disease modeling, drug screening, and the development of stem cell therapeutics.
authors.affiliation: From the Center for Regenerative Medicine, National Institutes of Health, Bethesda, Maryland 20892 and.
authors.forename: Mahendra
authors.initials: M
authors.lastname: Rao
authors.forename: Joel M
authors.initials: JM
authors.lastname: Gottesfeld
mesh_terms: D004353:Drug Evaluation, Preclinical; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology*; D033581:Stem Cell Transplantation
keywords: Gene Correction; Genomic Instability; Immunogenicity; Induced Pluripotent Stem Cells; Regenerative Medicine; Stem Cells; Toxicology